TNF and psoriasis: A study assessed the impact of the PGLYRP4–24 rs2916205 (C > T) polymorphism on the response to anti-TNF drugs (PASI 75 at 3 and 6 months) in patients of Spanish origin diagnosed with psoriasis (n = 144) [42] and found an association between the PGLYRP4–24 rs2916205-C allele and worse anti-TNF response at 3 months of treatment (OR = 3.62, CI95% = 1.00–13.07, p = 0.05) [42].